Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...

The stock's fall snapped a two-day winning streak.

In this article, we will take a look into Abbott Laboratories's (NYSE:ABT) DCF analysis, a reliable and data-driven approach ...

Abbott Laboratories closed $4.01 short of its 52-week high ($121.64), which the company reached on March 8th.

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Abbott Laboratories (ABT) stock saw a decline, ending the day at $114.88 which represents a decrease of $-3.25 or -2.75% from the prior close of $118.13. The stock opened at $117.5 and touched a low ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE: ABT) with an "overweight" rating and a price target of $131 ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...